---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001294"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:11:56.128207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024

## Summary
- Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.
- Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).
- ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.
- ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.
- ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024.

## SEC filing metadata
- accession: 0001171843-24-001294
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/f8k_031124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001294
- JSON: https://secwatch.observer/filing/0001171843-24-001294.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001294.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $87.7 million, EPS $(1.36).
  - Period: the year ended December 31, 2023
  - Net income: $87.7 million
  - EPS: $(1.36)
  - Result: reported results
  source text: Net losses for the year ended December 31, 2023 were $87.7 million or basic and diluted net loss per common share of $(1.36), compared to net losses of $96.0 million or basic and diluted net loss per common share of $(2.25) for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm
- Earnings Releases
  Aligos Therapeutics, Inc. reported the three months ended December 31, 2023 results: net income $27.9 million, EPS $(0.22).
  - Period: the three months ended December 31, 2023
  - Net income: $27.9 million
  - EPS: $(0.22)
  - Result: reported results
  source text: Net losses for the three months ended December 31, 2023 were $27.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $21.9 million or basic and diluted net loss per common share of $(0.51) for the three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184324001294/0001171843-24-001294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.